PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

Phase 4

Completed

Conditions: Major Coronary Event
Cerebrovascular Accident
Coronary Artery Bypass Graft
Angina, Unstable
Revascularization

First Posted Date: 2006-05-18

Last Posted Date: 2007-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 2800

Registration Number: NCT00327418

Locations: 🇬🇧
Pfizer Investigational Site, Wishaw, United Kingdom

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Phase 4

Completed

Conditions: Cardiovascular Disease
Cerebrovascular Accident
Coronary Heart Disease

First Posted Date: 2006-05-18

Last Posted Date: 2007-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 8600

Registration Number: NCT00327691

Locations: Pfizer Investigational Site

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Phase 2

Completed

Conditions: Dyslipidemia

First Posted Date: 2006-05-16

Last Posted Date: 2009-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT00326326

Locations: 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

Phase 4

Completed

Conditions: Macular Degeneration

Interventions: Drug: pegaptanib sodium (Macugen)

First Posted Date: 2006-05-10

Last Posted Date: 2010-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT00324116

Locations: 🇫🇷
Pfizer Investigational Site, Toulouse, France

Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: SU014813

First Posted Date: 2006-05-08

Last Posted Date: 2011-05-17

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT00322517

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PF-3512676 + Erlotinib
Drug: Erlotinib

First Posted Date: 2006-05-04

Last Posted Date: 2010-12-23

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00321815

Locations: 🇺🇸
Pfizer Investigational Site, Dalls, Texas, United States

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small Cell Lung

Interventions: Drug: pemetrexed + PF-3512676
Drug: pemetrexed

First Posted Date: 2006-05-03

Last Posted Date: 2009-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00321308

Locations: 🇮🇹
Pfizer Investigational Site, Torino, Italy

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Phase 3

Completed

Conditions: Seizures
Epilepsies, Partial
Epilepsy, Complex Partial
Epilepsy, Generalized
Epilepsy

Interventions: Drug: Placebo
Drug: Vanquix Auto-Injector (Diazepam Injection)

First Posted Date: 2006-04-27

Last Posted Date: 2016-09-23

Lead Sponsor: Pfizer

Target Recruit Count: 234

Registration Number: NCT00319501

Locations: 🇺🇸
Stein Life Child Neurology Medical Specialists Inc., Irvine, California, United States
🇺🇸
Lahey Clinic Medical Center, Burlington, Massachusetts, United States
🇺🇸
Morton Plant Hospital Pharmacy, Clearwater, Florida, United States

and more 82 locations

Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

Phase 4

Completed

Conditions: Sepsis

First Posted Date: 2006-04-27

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT00318552

Locations: 🇭🇺
Research Site, Veszprem, Hungary

Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis

Phase 4

Completed

Conditions: Pancreatitis

First Posted Date: 2006-04-27

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00318994

Locations: 🇨🇴
Research Site, Bogota, Colombia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy